Coşkun 2010.

Methods	Cohort study of methylphenidate treatment in participants with ADHD and comorbid anxiety‐ or depressive disorders
Participants	Number of participants screened: not stated Number of participants included: 7 Number of participants followed up: not stated Number of withdrawals: not stated Diagnosis of ADHD: DSM‐IV (subtype: combined (57%), inattentive (43%)) Age: mean 11.85 (SD 2.91), range: 8‐16 years old IQ: normal Sex: 4 males, 3 females Methylphenidate‐naïve: none Ethnicity: Turkish Country: Turkey Comorbidity: generalised anxiety (86%), social anxiety (86%), panic (29%), separation anxiety (29%), obsessive‐compulsive (29%) and major depressive disorder (14%), special phobia (29%) and agoraphobia (14%) Comedication: SSRIs (57%) Sociodemographics: not stated Inclusion criteria Meet criteria for diagnoses of ADHD, anxiety and/or depressive disorders based on DSM‐IV
Interventions	Methylphenidate type and dosage: immediate release (15‐20 mg/day), osmotic release oral system (18‐54 mg/day), IR/OROS (10‐18 mg) Administration schedule: not stated Duration of intervention: 4‐30 months, mean 14.28 (SD 9.41) Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Sleep problems: developed sleep problems (n = 4) worsening of pre‐existing sleep problems (n = 2) Appetite problems: significant decrease in appetite (n = 3) weight loss: same 3 patients (1 = −2 kg, 1 = −3 kg, 1 = −4 kg)
Notes	Sample calculation: not stated Ethics approval: not stated Funding/vested interests: the authors reported no conflict of interest related to this article Key conclusions of the study authors: young participants with diagnosis of ADHD and comorbid anxiety and depressive disorders may benefit from mirtazepine addition particularly in the presence of methylphenidate‐ or SSRI‐related sleep and/or appetite problems Comments from the review authors: the adverse events reported here are from before the start of the mirtazepine treatment which means the participants are under no treatment but methylphenidate Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: no Supplemental information received through personal email correspondence with the authors in August 2013 (Coşkun 2013c [pers comm])